Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/III Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Putamen Transplantation of NouvNeu001 Injection for Multiple System Atrophy

NCT07289477 is registered in ClinicalTrials.gov with iRegene Therapeutics Co., Ltd. as lead sponsor.

NCT NCT07289477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07289477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/III Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Putamen Transplantation of NouvNeu001 Injection for Multiple System Atrophy
Lead sponsor
iRegene Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
January 5, 2026
Completion date
July 31, 2031
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple system atrophy - parkinsonian subtype (msa-p)